Share This Article:

Primary Malignant Lymphoma of Prostate with Silent MYD88 Mutation

Abstract Full-Text HTML XML Download Download as PDF (Size:816KB) PP. 125-128
DOI: 10.4236/crcm.2014.33031    2,535 Downloads   3,438 Views  

ABSTRACT

We present a case of primary malignant lymphoma of the prostate in a 77-year-old Japanese man. Immunohistochemical examinations revealed the presence of a non-GCB subtype of DLBCL (CD10 (-), Bcl-6 (-), MUM1 (+)), and genetic analysis disclosed a lack of typical codon 206 or 265 missense mutation in MYD88, suggesting that the case was of type3 (non-GCB andnon-ABC), a subtype of DLBCL. Three courses of chemotherapy (rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)) were effective, and the patient has been free of the disease with no local or systemic recurrence for three years. Although the significance of silent mutation at hot spot of the highly oncogenic MYD88 gene in this case is unclear, a minute increase in translational efficiency by silent mutation may have contributed to the activation of MYD88.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Yoshida, K. , Kitazawa, R. , Komoda, M. , Ito, C. , Haraguchi, R. and Kitazawa, S. (2014) Primary Malignant Lymphoma of Prostate with Silent MYD88 Mutation. Case Reports in Clinical Medicine, 3, 125-128. doi: 10.4236/crcm.2014.33031.

References

[1] Sarris, A., Dimopoulos, M., Pugh, W. and Cabanillas, F. (1995) Primary Lymphoma of the Prostate: Good Outcome with Doxorubicin-Based Combination Chemotherapy. The Journal of Urology, 153, 1852-1854.
http://dx.doi.org/10.1016/S0022-5347(01)67330-0
[2] Hans, C.P., Weisenburger, D.D., Greiner, T.C., Gascoyne, R.D., Delabie, J., et al. (2004) Confirmation of the Molecular Classification of Diffuse Large B-Cell Lymphoma by Immunohistochemistry Using a Tissue Microarray. Blood, 103, 275-282. http://dx.doi.org/10.1182/blood-2003-05-1545
[3] Ngo, V.N., Young, R.M., Schmitz, R., Jhavar, S., Xiao, W., et al. (2011) Oncogenically Active MYD88 Mutations in human Lymphoma. Nature, 470, 115-119. http://dx.doi.org/10.1038/nature09671
[4] Bostwick, D.G., Iczkowski, K.A., Amin, M.B., Discigil, G. and Osborne, B. (1998) Malignant Lymphoma Involving the Prostate: Report of 62 Cases. Cancer, 83, 732-738.
http://dx.doi.org/10.1002/(SICI)1097-0142(19980815)83:4<732::AID-CNCR15>3.0.CO;2-T
[5] Pham-Ledard, A., Cappellen, D., Martinez, F., Vergier, B., Beylot-Barry, M., et al. (2012) MYD88 Somatic Mutation Is a Genetic Feature of Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. Journal of Investigative Dermatology, 132, 2118-2120. http://dx.doi.org/10.1038/jid.2012.102
[6] Treon, S.P., Xu, L., Yang, G., Zhou, Y., Liu, X., et al. (2012) MYD88 L265P Somatic Mutation in Waldenstrom’s Macroglobulinemia. The New England Journal of Medicine, 367, 826-833. http://dx.doi.org/10.1056/NEJMoa1200710
[7] Khosronezhad, N., Colagar, A.H. and Jorsarayi, S.G. (2014) T26248G-Transversion Mutation in Exon7 of the Putative Methyltransferase Nsun7 Gene Causes a Change in Protein Folding Associated with Reduced Sperm Motility in Asthenospermic Men. Reproduction, Fertility and Development. http://dx.doi.org/10.1071/RD13371

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.